IMPROVE Trial Results presented at IFCPC World Congress – DYSIS Medical

IMPROVE Trial Results presented at IFCPC World Congress

IMPROVE Trial Results presented at IFCPC World Congress

DYSIS clinical outcomes presented in four abstracts at The International Federation of Cervical Pathology and Colposcopy (IFCPC) World Congress


Edinburgh, Scotland – April 4, 2017 – DYSIS Medical, Ltd. announced today that an oral abstract and three posters have been selected to be presented at the joint meeting of the IFCPC and the American Society of Cervical Colposcopy and Pathology (ASCCP).

The oral abstract will be presented by the esteemed Professor Warner Huh, a world-renowned Gynecologic Oncologist and Director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham. He will present data on standard colposcopy practice in over 3,400 women and 160 providers at 44 U.S. community clinics as part of the IMPROVE-COLPO study.

The first poster, to be presented by Orlando Gynecologic Oncologist, Dr. Sara DeNardis, studied a population of borderline Pap smear patients with high-risk HPV from the IMPROVE-COLPO study.  It demonstrated, in over 3,000 women, an improved detection rate for high-grade lesions of 51%, with a decrease in the percentage of false positive biopsies, compared to traditional colposcopy. The second, by Dr. Christina Founta, Consultant Gynecologist of the Taunton & Somerset HS Foundation Trust, also demonstrated a 28% increase in detection of high-grade lesions in a low-grade Pap smear population and with fewer biopsies to detect each case compared to a traditional colposcopy control group.

The final poster was a case study by Angelika Kaufmann, MD (Northern Gynaecological Oncology Centre, Gateshead NHS Foundation Trust), that demonstrated the value of using the very standardized, objective, quantified approach that the DYSIS cervical map offers, to track young women and avoid unnecessary treatment.  In upwards of 50% of these women, certain lesions may resolve themselves.  Since treatment can cause complications in pregnancy, this may offer a way to conservatively monitor some young women and potentially avoid or delay treatment until after they have completed their families.

DYSIS Medical’s CEO, Alastair Atkinson commented, “We are thrilled to have our first oral presentation of the IMPROVE-COLPO study results on a population of colposcopy providers never studied before, and to see two additional analysis of studies in both the UK and USA continue to demonstrate the outstanding clinical outcomes generated by the DYSIS cervical map.  To also see the value the SMARTtrack feature offers, to enable conservative management that might reduce potential complications in pregnancy, is especially rewarding.”

DYSIS Medical, Inc.

Tel: +1-813-367-3564

Alastair Atkinson


B-Roll available


DYSIS Medical Ltd

DYSIS Medical Ltd has its global headquarters in Edinburgh and US Headquarters in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: or call 844-DYSISMED.